New device is the only commercially available bedside monitor designed for home care and sleep study settings
20/11/2014 — DUBLIN, Ireland — (BUSINESS WIRE)
Covidien (NYSE: COV) today announced CE Mark approval for its Nellcor™ Bedside SpO2 Patient Monitoring System, PM100N. The system currently is available in the European Economic Area (EEA), Australia and New Zealand. The Nellcor™ Bedside SpO2 Patient Monitoring System is the only commercially available bedside pulse oximetry (SpO2) monitor featuring home care and sleep study modes that complies with standards for medical electrical equipment used in the home health care environment.
The new system provides continuous monitoring of blood oxygenation (SpO2) and pulse rate to help clinicians detect and respond to dangerous respiratory events sooner, along with patient trend data to allow clinicians to evaluate a patient’s clinical course. With Covidien-exclusive digital signal processing, the PM100N offers industry-leading speed and accuracy, and reliable pulse oximetry readings—even during low patient perfusion, motion and other forms of signal interference.1
“At Covidien, we’re dedicated to improving patient care and safety, not only in the hospital, but also in home health care,” said Matt Anderson, vice president and general manager, Patient Monitoring, Respiratory and Monitoring Solutions, Covidien.
The pulse oximetry system was designed with features to help improve patient safety. It incorporates SatSeconds™ Alarm Management technology—available only on Covidien patient monitors— to help distinguish between serious and minor events, reducing clinically insignificant desaturation alarms. The monitor can also be password-protected to prevent lay users from inadvertently modifying settings.
“Just because a patient is not in the hospital setting does not mean he or she no longer needs on-going care,” said Dr. Scott Kelley, chief medical officer, Respiratory and Monitoring Solutions, Covidien. “The availability of solutions to enable safe, quality care for patients in all settings, including the home, is something we are focused on at Covidien. This new system includes all of the leading Nellcor™ technology that clinicians have trusted for more than 30 years, with additional features that make it well suited to the home health care environment.”
More information on the PM100N and the entire Nellcor™ pulse oximetry portfolio is available by visiting www.covidien.com/rms/products/pulse-oximetry .
1. Internal Covidien data on file
Covidien is a global health care leader that understands the challenges faced by providers and their patients and works to address them with innovative medical technology solutions and patient care products. Inspired by patients and caregivers, Covidien’s team of dedicated professionals is privileged to help save and improve lives around the world. With more than 39,000 employees, Covidien operates in 150-plus countries and had 2014 revenue of $10.7 billion. To learn more about our business visit www.covidien.com or follow us on Twitter.
Rhonda Luniak, 303-406-8743
Vice President, R&MS Communications
Lisa Clemence, 508-452-4375
Director, Corporate Communications
Coleman Lannum, CFA, 508-452-4343
Vice President, Investor Relations
Todd Carpenter, 508-452-4363
Senior Director, Investor Relations
KEYWORDS: Europe Ireland
INDUSTRY KEYWORDS: Health Hospitals Medical Devices FDA Managed Care